In light of encouraging results, Cell>Point said it has closed the Phase II part of its Phase II/III study involving the use of 99mTc-EC-G in assessing the presence and reach of nonsmall-cell lung cancer in patients. As a next step, the company will submit a report to the FDA regarding the results of the Phase II study and discuss measures in conducting the Phase III part of the trial.

Full Story:
Business Wire

Related Summaries